Готові списки джерел за темами / Glioma patients

Добірка наукової літератури з теми "Glioma patients"

Автор: Grafiati
Опубліковано: 6 вересня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Зміст

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Glioma patients".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Glioma patients"

1

Jiang, Chongming, Evelien Schaafsma, Yanding Zhao, Thinh Nguyen, Kenneth Zhu, and Chao Cheng. "Abstract LB528: A microglia associated gene signature predicts survival risk in glioma patients." Cancer Research 82, no. 12_Supplement (June 15, 2022): LB528. http://dx.doi.org/10.1158/1538-7445.am2022-lb528.

Повний текст джерела
Анотація:
Abstract Background: Gliomas are common tumors that affect the brain and spinal cord. A complex tumor microenvironment is one of the leading reasons for a poor prognosis in glioma patients. Microglia, as part of the immune microenvironment of gliomas, may facilitate glioma growth and invasion. However, the correlation between the microglia abundance and glioma prognosis has not been clarified. Method: Our goal was to examine the relationship between microglia abundance and glioma prognosis. We analyzed the single-cell RNA sequences of human and mouse glioma cells to identify microglia marker genes. Then, we built a LASSO Cox regression model of microglia abundance signatures in gliomas. The Cancer Genome Atlas (TCGA) dataset (Low-grade gliomas, LGG) was used as the training cohort. The Repository of Molecular Brain Neoplasia Data (REMBRANDT) dataset and Chinese Glioma Genome Atlas (CGGA) dataset was used to validate the model as the validation cohorts. Findings: Overall survival was significantly lower in those with a high level of microglia infiltration. Additionally, we found that microglia could interact with the tumor microenvironment and genomic features of gliomas, making microglia abundance negatively associated with the prognosis of glioma patients. Microglia abundance was positively correlated with immune genes expression and immune-related pathways. By applying our LASSO Cox regression model to gliomas, we found that patients with high-risk scores had significantly shorter overall survival (OS) than those with low-risk scores. Conclusions: Taken together, our findings suggest that microglia abundance may be negatively associated with survival in gliomas. Based on the novel microglia abundance signatures, we developed a high accuracy LASSO Cox regression model. In this study, we demonstrated that the model accurately predicted the prognosis of glioma patients and could offer new therapeutic targets for microglial-directed therapies. Keywords: Gliomas; Microglia abundance; LASSO Cox regression; TCGA; Signature.- 1 - Citation Format: Chongming Jiang, Evelien Schaafsma, Yanding Zhao, Thinh Nguyen, Kenneth Zhu, Chao Cheng. A microglia associated gene signature predicts survival risk in glioma patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB528.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Zhao, Shiguang. "BIOM-63. DIAGNOSIS AND PROGNOSTIC SIGNIFICANCE OF CIRCULATING miR-2276-5p IN PLASMA OF GLIOMA PATIENTS." Neuro-Oncology 22, Supplement_2 (November 2020): ii15. http://dx.doi.org/10.1093/neuonc/noaa215.060.

Повний текст джерела
Анотація:
Abstract Circulating microRNAs (miRNAs) in plasma have the potential to become diagnostic and prognostic biomarkers for various cancers. This study hopes to use plasma circulating miRNAs as biomarkers for diagnosis and prognosis of glioma patients. METHOD: In this study, the plasma circulating miRNAs of 124 patients with glioma and 36 controls was collected to detect the relative expression of miR-2276-5p, and the specificity and sensitivity of the diagnosis were verified by ROC curve. The follow-up survival status was analyzed by cox regression analysis. RESULT: In the GSE 139031 database, it was found that the expression of circulating miR-2276-5p in plasma of glioma patients was significantly lower than that of patients with non-gliomas. Using our plasma samples, and it is indicated that the expression of circulating miR-2276-5p in plasma is lower than that of healthy patients, and compared with low-grade gliomas, patients with high-grade gliomas have a lower expression of circulating miR-2276-5p. ROC curve analysis found that the AUC value was 0.851. The low expression of circulating miR-2276-5p in plasma of glioma patients indicates a poor prognosis of glioma patients, After univariate and multifactorial cox regression analysis, which can be used as an independent prognostic risk factor for glioma patients (P< 0.05). CONCLUSION: The expression of circulating miR-2276-5p in plasma of glioma patients was significantly lower than that of the control group, compared with low-grade gliomas, patients with high-grade gliomas have a lower expression of circulating miR-2276-5p. The lower the relative expression of circulating miR-2276-5p indicated that glioma patients had a worse prognosis.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Li, shaoqun, Mingyao Lai, Jiangfen Zhou, junjie Zhen, and Linbo Cai. "PATH-22. GENETIC VARIATION BETWEEN IDH MUTANT AND IDH WILD-TYPE GLIOMA." Neuro-Oncology 23, Supplement_6 (November 2, 2021): vi119. http://dx.doi.org/10.1093/neuonc/noab196.474.

Повний текст джерела
Анотація:
Abstract OBJECTIVE The prognosis of IDH mutant glioma was significantly different from that of IDH wild-type glioma. In order to explore the differences between them at the genetic level, we analyzed the genetic results of IDH mutant and IDH wild-type glioma. METHODS This study analyzed the clinical data and genetic results of 45 glioma patients from Jan. 2017 to Dec. 2019, exploring relevant prognostic indicators and the difference in genetic profile between IDH mutant glioma and IDH wild-type glioma. RESULTS 45 patients were included in this study, including 15 IDH mutant glioma patients and 30 IDH wild-type glioma patients. Genetic analysis showed that there was no difference in tumor mutation burden (TMB) and microsatellite instability (MSI) between IDH mutant glioma and IDH wild-type glioma. But somatic mutation between IDH mutant and IDH wild-type glioma was different. The expressions of IDH1, CIC, SYNE1 and TP53 were different in the two groups, among which IDH1 and CIC were more significantly different. Copy number variations (CNV) was also different between IDH mutant glioma and IDH wild-type glioma. STIL occured more frequently in IDH wild-type gliomas. Genetic analysis also showed the difference in variant allel frequence (VAF). IDH mutant gliomas were more likely to be combined with ATRX and TP53 mutations, while IDH wild-type gliomas, in addition to the combination of TP53 mutations, often also combined with the mutations of NF1, BRAF and PTEN. In survival analysis, glioma with IDH mutation has a good prognosis, and IDH wild-type patients have a poor prognosis. In IDH wild-type patients, patients with PTEN mutation have a worse prognosis. CONCLUSION There is an obvious genetic difference between IDH mutation and IDH wild-type glioma, and PTEN mutation is a poor prognostic factor for IDH wild-type patients.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Priambada, Dody, Muhamad Thohar Arifin, Surya Pratama Briliantika, Dian Widyaningrum, Abdi Saputro, Azka Tajussyarof El Muzakka, Yuriz Bakhtiar, Krisna Tsaniadi Prihastomo, and Zainal Muttaqin. "Serum GFAP and EGFR as Supportive Diagnostic Biomarker of Glioma Patients: A Single-Center Study." Open Access Macedonian Journal of Medical Sciences 10, B (April 20, 2022): 1093–96. http://dx.doi.org/10.3889/oamjms.2022.9021.

Повний текст джерела
Анотація:
Background : High grade Gliomas (HGGs) (World Health Organization grade III and IV) are aggressive brain tumors with a poor prognosis. Serum concentrations of GFAP and EGFR are theoretically raised in glioma patients, especially primary HGGs Aim : To look at serum levels of GFAP and EGFR in patients with Gliomas (Low Grade and High-Grade Glioma) and see if they were related to clinical outcome, MRI parameter and pathological features. Method : Between 2020-2021, pre-operative blood samples were taken from 39 patients with radiologically diagnosed glioma who were performed for tumour excision. The time between blood collection and surgical resection was an average of 10 days. GFAP and EGFR serum were compared in glioma and non-glioma patients. Result : Glioma patients had average of serum GFAP 747.93 + 1349.49 pg/ml and average of Serum EGFR 9.25 + 3.17 ng/ml. Non glioma average of GFAP and EGFR respectively were 292.91 + 369.30 pg/ml and 7.81 + 3.38 ng/ml.From all variable, we performed normality test using the Saphiro-wilk normality test and all variable were no normally distribution with p<0.05 Conclusion : Circulating GFAP and EGFR are promising method for “supportive” methods for differentiate between glioma and non-glioma patients, especially high grade glioma
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Kim, Junhyung, Min Woo Park, Young Joon Park, Ju Won Ahn, Jeong Min Sim, Suwan Kim, Jinhyung Heo, et al. "miR-542-3p Contributes to the HK2-Mediated High Glycolytic Phenotype in Human Glioma Cells." Genes 12, no. 5 (April 23, 2021): 633. http://dx.doi.org/10.3390/genes12050633.

Повний текст джерела
Анотація:
(1) Background: The elevation of glucose metabolism is linked to high-grade gliomas such as glioblastoma multiforme (GBM). The high glycolytic phenotype is associated with cellular proliferation and resistance to treatment with chemotherapeutic agents in GBM. MicroRNA-542-3p (miR-542-3p) has been implicated in several tumors including gliomas. However, the role of miR-542-3p in glucose metabolism in human gliomas remains unclear; (2) Methods: We measured the levels of cellular proliferation in human glioma cells. We measured the glycolytic activity in miR-542-3p knockdown and over-expressed human glioma cells. We measured the levels of miR-542-3p and HK2 in glioma tissues from patients with low- and high-grade gliomas using imaging analysis; (3) Results: We show that knockdown of miR-542-3p significantly suppressed cellular proliferation in human glioma cells. Knockdown of miR-542-3p suppressed HK2-induced glycolytic activity in human glioma cells. Consistently, over-expression of miR-542-3p increased HK2-induced glycolytic activity in human glioma cells. The levels of miR-542-3p and HK2 were significantly elevated in glioma tissues of patients with high-grade gliomas relative to that in low-grade gliomas. The elevation of HK2 levels in patients with high-grade gliomas were positively correlated with the high levels of miR-542-3p in GBM and low-grade gliomas (LGG) based on the datasets from the Cancer Genome Atlas (TCGA) database. Moreover, the high levels of miR-542-3p were associated with poor survival rate in the TCGA database; (4) Conclusions: miR-542-3p contributes to the HK2-mediated high glycolytic phenotype in human glioma cells.
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Kim, Junhyung, Min Woo Park, Ju Won Ahn, Jeong Min Sim, Suwan Kim, Young Joon Park, Jinhyung Heo, et al. "TAMI-47. MIR-542-3P CONTRIBUTES TO THE HK2-MEDIATED HIGH GLYCOLYTIC PHENOTYPE IN HUMAN GLIOMA CELLS." Neuro-Oncology 23, Supplement_6 (November 2, 2021): vi208. http://dx.doi.org/10.1093/neuonc/noab196.830.

Повний текст джерела
Анотація:
Abstract BACKGROUND The elevation of glucose metabolism is linked to high-grade gliomas such as glioblastoma multiforme (GBM). The high glycolytic phenotype is associated with cellular proliferation and resistance to treatment with chemotherapeutic agents in GBM. MicroRNA-542-3p (miR-542-3p) has been implicated in several tumors including gliomas. However, the role of miR-542-3p in glucose metabolism in human gliomas remains unclear. METHODS We measured the levels of cellular proliferation in human glioma cells. We measured the glycolytic activity in miR-542-3p knockdown and over-expressed human glioma cells. We measured the levels of miR-542-3p and HK2 in glioma tissues from patients with low- and high-grade gliomas using imaging analysis. RESULTS We show that knockdown of miR-542-3p significantly suppressed cellular proliferation in human glioma cells. Knockdown of miR-542-3p suppressed HK2-induced glycolytic activity in human glioma cells. Consistently, over-expression of miR-542-3p increased HK2-induced glycolytic activity in human glioma cells. The levels of miR-542-3p and HK2 were significantly elevated in glioma tissues of patients with high-grade gliomas relative to that in low-grade gliomas. The elevation of HK2 levels in patients with high-grade gliomas were positively correlated with the high levels of miR-542-3p in GBM and low-grade gliomas (LGG) based on the datasets from the Cancer Genome Atlas (TCGA) database. Moreover, the high levels of miR-542-3p were associated with poor survival rate in the TCGA database. CONCLUSIONS miR-542-3p contributes to the HK2-mediated high glycolytic phenotype in human glioma cells.
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Tran Anh Duc, Nguyen Thanh Bac, Nguyen Van Ba, and Nguyen Duc Lien. "Study on some clinical features, histopathology and mutations in IDH, P53 genes, mgmt methylation in patients with high-grade glioma." VietNam Military Medical Unisversity 47, no. 6 (September 8, 2022): 191–99. http://dx.doi.org/10.56535/jmpm.v47i6.66.

Повний текст джерела
Анотація:
Objectives: To describe some genes' clinical, histopathological and mutational characteristics in patients with high-grade glioma. Subjects and methods: A descriptive study was conducted on 52 high-grade glioma patients who met the research criteria at Vietnam National Cancer Hospital (Tan Trieu campus) from 1st January 2019 to 12th December 2020. Results: The mean age of the study patients was 45.2 ± 14.4; men accounted for the majority (61.5%). The main reason for the patient's admission was headache, hemiplegia, epilepsy... The average Karnofski score of the patient was 68.5 ± 14.7 points. The results of IDH gene mutation show that patients with grade III GCC have a higher positive rate than grade IV, P53 gene mutations occur mainly in grade IV GCC patients, MGMT methylation occurs on 57% of study patients. Conclusion: High-grade glioma is common in men aged over 40. Common clinical symptoms are headache, hemiplegia, and epilepsy. IDH gene mutations are seen in grade III gliomas, P53 gene mutations are common in grade IV gliomas. * Keywords: High-grade glioma; IDH gene mutation; P53 gene mutation; MGMT methylation.
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Vattemi, Emanuela, Giovanna Cipollini, Cristina Dealis, Lorena Rossi, Susanne Baier, Elisabetta Cretella, Giovanni Di Meglio, et al. "Genetic polymorphisms of EGF 5'-UTR in patients with glioma: A possible predictive marker of outcome." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): e13009-e13009. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e13009.

Повний текст джерела
Анотація:
e13009 Background: Epidermal growth factor (EGF) plays an important role in carcinogenesis. An adenine (A) to guanine (G) single nucleotide polymorphism at position 61 in the 5'-untranslated region (5'-UTR) of the EGF gene has been found to be associated with levels of EGF production and contribute to the risk of glioma. However, published data are contradictory. EGF +61G/A polymorphism may contribute to the risk of glioma in different ethnic group. Patients with glioma and GG genotype have been reported to have a risk of poorer otucome than patients with AA genotype. Purpose of this study is to investigate the potential role of this polymorphism in cancer progression and its role as predictive marker of outcome in glioma caucasian patients. Methods: EGF 61A/G polymorphism (rs4444903) was analyzed in glioma patients and was determined by means of Polymerase Chain Reaction and Direct Sequencing method (GenBank reference sequence-accession no. AC005509) from blood samples. Association of this genetic polymorphism with clinical and pathological data of patients was evaluated. Results: We investigated EGF +61G/A polymorphism in 24 glioma patients . EGF +61G allele has been found in 67% of glioma patients (25% G/G genotype and 42% A/G genotype). In astrocytomas, EGF +61G allele represents a 83% frequency; in glioblastomas and in oligodendrogliomas, EGF +61G allele frequency represents respectively 71% and 50%. In WHO IV gliomas, the EGF +61G allele represents a 63% frequency, (27% G/G and 36% A/G ), in WHO III gliomas a 77% frequency (33% G/G and 44% A/G ) and in WHO II gliomas a 50% frequency (100% A/G ). Median PFS of glioblastoma patients was 9 months. 83% of glioblastoma patients with a relapsing disease showed the G/G and A/G genotype. No difference was detected in the others histotypes. Conclusions: Our data conferm previous studies which reported G allele as a risk factor for glioma in Caucasian. G/A and G/G genotypes seem to be more rappresentative in high grade gliomas . Despite limited number of patients, our study supports the predictive role of EGF 61 A/G polymorphism in GBM. Additional large studies are warranted to confirm the role of EGF polymorphism as indipendent prognostic factor in glioma.
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Bracci, Paige, Terri Rice, Helen Hansen, Stephen Francis, Sean Lee, Lucie McCoy, Pavan Shrestha, et al. "EPID-08. PRE-SURGERY IMMUNE PROFILES OF ADULT GLIOMA PATIENTS." Neuro-Oncology 22, Supplement_2 (November 2020): ii79—ii80. http://dx.doi.org/10.1093/neuonc/noaa215.326.

Повний текст джерела
Анотація:
Abstract Changes in glioma patients’ immune profiles over the course of disease may predict outcomes. DNA based immunomethylomics quantifies blood immune cells based on cell specific DNA methylation signatures. To assess changes in immune profiles, we are longitudinally collecting blood samples from glioma patients pre-surgery and at other clinically relevant time points. Here we report patients’ pre-surgery immune profiles. All patients underwent biopsy or resection of a presumed new glioma or recurrent lower grade glioma. Blood DNA methylation was assessed with Illumina EPIC methylation arrays. Relative cell fractions of CD4, CD8, B-cells, natural killer cells, monocytes, and neutrophils, were estimated via our validated deconvolution algorithm. Total nucleated cell counts from Nexcelom cytometry were used to compute absolute cell counts. Other measures include total lymphocytes, CD4/CD8 ratio, neutrophil to lymphocyte ratio (NLR), and lymphocyte to monocyte ratio (LMR)). The first 125 participants includes 56 newly diagnosed glioblastomas (GBM), 28 newly diagnosed grade II-III gliomas, and 41 recurrent grade II-III gliomas. Median patient age is 49 years. 53 (43%) had recent dexamethasone exposure. In overall non-parametric analyses, most cell subsets, especially CD4, differed across grade, diagnosis group, WHO classification and dexamethasone exposure. In post-hoc pairwise analyses, immune profiles of IDH wildtype GBM patients who had taken dexamethasone differed from patients with GBM or grade II-III glioma who had not taken dexamethasone; they had clinically relevant and statistically significantly lower absolute CD4 counts, total white cell counts, and percent of total lymphocytes, and higher absolute neutrophil counts, NLR and LMR. However, some dexamethasone naïve GBM patients also had altered immune profiles. Comparisons of relative immune cell fractions with those from 454 non-glioma controls from the UCSF Adult Glioma Study showed that across grade and WHO classification, for the most part, immune profiles of glioma patients not exposed to dexamethasone did not differ from controls.
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Li, D., Y. Chen, C. Guo, Q. Yang, S. Wu, Y. Xia, J. Zeng, et al. "P03.09 Real world management and prognosis of glioma patients:SYSUCC report from China." Neuro-Oncology 21, Supplement_3 (August 2019): iii26—iii27. http://dx.doi.org/10.1093/neuonc/noz126.090.

Повний текст джерела
Анотація:
Abstract Background: The conventional way of patient treatment should be following guidelines. While in clinical practice, patients received treatments very often away from suggested guideline. In this report, we reviewed glioma patients received real world treatment at Sun Yat-sen University Cancer Center (SYSUCC) and results of this patient series. Methods: Total of 1215 glioma patients received surgery at SYSUCC from 2000 to 2017 were enclosed for analysis. The pathologic diagnosis of patients has followed WHO classification (initially 2007 standard, than 2016 standard). Results: A total of 1001 newly diagnosed brain glioma patients were analyzed, including 90 cases WHO grade I, 307 grade II, 239 grade III and 365 grade IV. The median age of onset was 14 (1–75), 35 (2–69), 41 (8–82) and 50 (2–86) years old, respectively, for grade I, II, III and IV glioma patients. Tumor total resection was achieved in 567 patients (57.5%). Among all patients, 331 high-grade gliomas (54.8%) and 159 low-grade glioma (40.1%) received radiotherapy, whereas 285 high-grade gliomas (47.1%) and 80 low-grade tumors (20.2%) received chemotherapy. Among high-grade gliomas, the median OS of glioblastoma, anaplastic astrocytoma and anaplastic oligodendroglial tumors were 17.7 months (15.7–19.7 months), 33.7 months (24.0–43.4 months) and 110.6 months (43.5–177.7 months), respectively, whereas the median OS of low-grade gliomas was not reach. The 5-year survival rate of grade I, II, III and IV gliomas was 94.7%, 73.7%, 45.1% and 18.6%, respectively. Multivariate analysis identified that onset age, Karnofsky performance status, tumor location, preoperative seizure, pathological subtype, resection extent and post-surgical treatment were independent predictors of OS for patients with high-grade gliomas. Patients received post-surgical radiotherapy and (or) chemotherapy had better survival than those without adjuvant treatment (grade III: 53.3 vs. 20.6 months, p =0.012; grade IV: 22.9 vs. 12.3 months, p < 0.001). For low-grade gliomas, patients’ age, Ki-67 index, tumor subtype and resection extent were associated with clinical outcomes. Conclusions: Glioma patients received treatments do not always following guidelines in clinical practice. Although standard care for patients may beneficial for prognosis, personalized treatment may more acceptable for patients and even resulting better outcome which should keep in mind in routine clinical practice.
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Дисертації з теми "Glioma patients"

1

Lilja, Åsa. "Psychoneurooncology psychological dynamics in glioma patients /." Lund : Dept. of Psychology, Lund University, 1992. http://books.google.com/books?id=SnZrAAAAMAAJ.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Lombardi, Giuseppe. "2-Hydroxyglutarate as a biomarker in glioma patients." Doctoral thesis, Università degli studi di Padova, 2014. http://hdl.handle.net/11577/3423791.

Повний текст джерела
Анотація:
Background: mutation of IDH1 gene is a prognostic factor and a diagnostic hallmark of gliomas. Mutant IDH1 enzyme can convert α-KG into 2-Hydroxyglutarate (2HG) and mutated gliomas have elevated amounts of intracellular 2HG. Since 2HG is a small molecule it seems possible that it could reach the systemic circulation and to be excreted by urine. And so, we analyzed 2HG concentration in plasma and urine in glioma patients to identify a surrogate biomarker of IDH1 gene mutation. Materials and Methods: All patients had a prior histological confirmation of glioma, a recent brain MRI (within 2 weeks) showing the neoplastic lesions. The exclusion criteria were any chemotherapy performed within 28 days prior, other neoplastic and metabolic diseases. Plasma and urine samples were taken from all patients and 2HG concentrations determined by liquid chromatography tandem mass spectrometry; exon 4 of IDH1 genes were analyzed by Sanger sequencing; differences in metabolite concentrations between mutant and wild-type IDH1 patients were examined with the Mann-Whitney U test for non-parametric data; Student’s t-test was used to compare parametric data. ROC curve was used to evaluate the cut off value of the 2HG biomarker. Results: 84 patients were enrolled: 38 with IDH1 mutated and 46 IDH1 wild-type. All the mutations were R132H. Among patients with mutant IDH1 we had 21 highgrade gliomas (HGG) and 17 low-grade gliomas (LGG); among patients with IDH wild-type we had 35 HGG and 11 LGG.. In all patients we analyzed the mean 2HG concentration in plasma (P_2HG), in urine (U_2HG) and the ratio between P_2HG and U_2HG (R_2HG). We found an important significant difference in R_2HG between glioma patients with and without IDH1 mutation (22.2 versus 15.6, respectively, p<0.0001). The optimal cut-off value of R_2HG to identify glioma patients with and without IDH mutation was 19 (sensitivity 63%, specificity 76%, accuracy 70%); in only PTS with HGG the optimal cut-off value was 20 (sensitivity 76%, specificity 89%, accuracy 84%, positive predictive value 80%, negative predictive value 86%). No associations between the grade or size of tumor and R_2HG were found. In 7 patients with highgrade gliomas we found a correlation between R_2HG value and response to treatment. Conclusions: analyzing R_2HG derived from individual plasma and urine 2HG levels is possible discriminate glioma patients with and without IDH mutation, in particular in high grade gliomas. Moreover, a larger samples need to be analyzed to investigate this method in patients follow-up for recurrence detection and to monitor treatment efficacy.
Background: la mutazione del gene IDH1 rappresenta un importante fattore prognostico e diagnostico per i tumori gliali. L’enzima IDH1 avente la mutazione ha la capacità di convertire α-KG in 2-Idrossiglutarato (2HG) e i gliomi mutati hanno una elevata concentrazione di 2HG all’interno delle cellule tumorali. Poichè 2HG è una piccola molecola, tale metabolita potrebbe raggiungere la circolazione sistemica ed essere escreta con le urine. Per tale ragione, nel nostro studio abbiamo analizzato la concentrazione di 2HG nel plasma e nelle urine nei pazienti con glioma per identificare un biomarcatore surrogato della presenza della mutazione IDH1. Materiali e Metodi: per l’arruolamento, tutti i pazienti dovevano avere avuto una precedente conferma istologica di glioma, una recente risonanza magnetica cerebrale (entro 2 settimane) mostrante la lesione tumorale. Qualsiasi chemioterapia eseguita nei 28 giorni precedenti l’analisi del metabolita, la presenza di altre malattie tumorali e malattie metaboliche escludevano l’arruolamento del paziente. Campioni plasmatici e urinari sono stati ottenuti da tutti i pazienti e le concentrazioni di 2HG ottenute mediante cromatografia liquida-spettrometria di massa; il test di Mann-Whitney è stato usato per calcolare le differenze di concentrazione dei metaboliti tra pazienti con IDH1 mutato e non-mutato, per dati non parametrici; il test di Student per comparare dati parametrici. La curva ROC è stata usata per calcolare il valore di cut-off del 2HG come biomarcatore. Risultati: sono stati arruolati 84 pazienti: 38 con IDH1 mutato e 46 con IDH1 wildtype. Tutte le mutazioni sono state R132H. Tra i pazienti con mutazione IDH1 abbiamo avuto 21 gliomi ad alto grado (HGG) e 17 gliomi a basso grado (LGG). Tra i pazienti con IDH1 wild-type abbiamo avuto 35 pazienti con HGG e 11 con LGG. In tutti i pazienti abbiamo analizzato la concentrazione media di 2HG nel plasma (P_2HG), nell’urina (U_2HG) e il rapporto tra la concentrazione plasmatica e urinaria (R_2HG). E’ emersa una importante differenza statisticamente significativa per l’R_2HG tra pazienti con e senza mutazione dell’IDH1 (22.2 verso 15.6, p<0.0001). Il cut-off ottimale di R_2HG per identificare lo stato mutazionale di IDH1 nei pazienti con glioma è risultato essere 19 (sensibilità 63%, specificità 76%, accuratezza 70%); nei soli pazienti con glioma ad alto grado il cut-off ottimale è risultato essere 20 (sensibilità 76%, specificità 89%, accuratezza 84%, valore predittivo positivo 80%, valore predittivo negativo 86%). Non è emersa nessuna associazione tra il grado o la dimensione del tumore con il valore di R_2HG. In 7 pazienti con glioma ad alto grado analizzati abbiamo, inoltre, trovato una correlazione tra il valore di R_2HG e la risposta al trattamento. Conclusioni: attraverso l’analisi di R_2HG, derivato dalla concentrazione plasmatica e urinaria di 2HG, è possibile discriminare gliomi con e senza mutazione IDH1, soprattutto in gliomi di alto grado. Occorrerà analizzare un campione più grande di pazienti con glioma per investigare tale metodica anche nel follow up allo scopo di individuare precocemente la recidiva di malattia e per monitorare l’efficacia del trattamento.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Dan, Michael. "Human anti-glioma monoclonal antibodies from patients with neurological tumors." Thesis, McGill University, 1989. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=74367.

Повний текст джерела
Анотація:
The current management of malignant gliomas is unsatisfactory compared to other solid tumors. Expected median survival is less than one year with even the best of care. At some point in their illness, most patients with neurological tumors are capable of mounting an immune response to their disease. This study focused on the humoral immune response of brain tumor patients by preparing human-human B cell hybridomas from autologous peripheral blood lymphocytes and a human myeloma-like cell line, designated as TM-H2-SP2. Eighteen fusions were successfully performed, and 15.8% of all microwells screened contained human immunoglobulin with anti-tumor activity. Five hybridomas, designated as BT27/1A2, BT27/2A3, BT32/A6, BT34/A5, and BT54/B8 were selected for detailed study. All five produced monoclonal IgM in a range of 2.4-44 $ mu$g/ml, had a similar (but not identical) pattern of reactivity against a panel of human tumor cell lines, and did not react with normal human astrocytes. All five human monoclonal antibodies (HmAbs) recognized a subpopulation of tumor cells based on multiparameter flow cytometric studies. Cell sorting experiments suggested that the identified subpopulation may share certain properties with hypothetical tumor stem cells. Preliminary antigen characterization indicated that the HmAbs are directed to cell surface glycolipids. These HmAbs possess certain properties of reactivity that suggest potential roles for them in the future diagnosis and clinical management of human malignant gliomas.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Gittleman, Haley Rebecca. "Nomograms and Sex Differences in Survival for Patients with Glioma." Case Western Reserve University School of Graduate Studies / OhioLINK, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=case1562341173580061.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

van, Ierschot Fleur Céline. "Monitoring of reading and spelling in glioma patients undergoing awake surgery." Doctoral thesis, Università degli studi di Trento, 2018. https://hdl.handle.net/11572/367937.

Повний текст джерела
Анотація:
One of the main aims of awake surgery for glioma patients is to preserve quality of life, while maximizing tumor resection. Focusing on an important yet understudied aspect of quality of life, this thesis investigates to what extent written language may be affected by a glioma or glioma surgery. By reviewing current assessments of reading and spelling in awake surgery studies, we aimed to provide a better understanding of how neuroanatomical theories may guide neurosurgical practice, and to evaluate how examinations of written language in glioma patients can be improved. To provide a direct clinical application for this knowledge, we developed a theory-driven written language battery specifically for glioma patients. Lastly, we tested its efficacy and evaluated reading and spelling performance in neurosurgical practice. The studies in this thesis have provided a better understanding of written language in neurosurgical practice. In particular, it has contributed to prediction and prevention of written language disorders in glioma patients undergoing awake surgery, and it has resulted in a valid examination tool to carefully monitor reading and spelling in this patient group.
Стилі APA, Harvard, Vancouver, ISO та ін.
6

van, Ierschot Fleur Céline. "Monitoring of reading and spelling in glioma patients undergoing awake surgery." Doctoral thesis, University of Trento, 2018. http://eprints-phd.biblio.unitn.it/2834/1/FvI_PhD_thesis.pdf.

Повний текст джерела
Анотація:
One of the main aims of awake surgery for glioma patients is to preserve quality of life, while maximizing tumor resection. Focusing on an important yet understudied aspect of quality of life, this thesis investigates to what extent written language may be affected by a glioma or glioma surgery. By reviewing current assessments of reading and spelling in awake surgery studies, we aimed to provide a better understanding of how neuroanatomical theories may guide neurosurgical practice, and to evaluate how examinations of written language in glioma patients can be improved. To provide a direct clinical application for this knowledge, we developed a theory-driven written language battery specifically for glioma patients. Lastly, we tested its efficacy and evaluated reading and spelling performance in neurosurgical practice. The studies in this thesis have provided a better understanding of written language in neurosurgical practice. In particular, it has contributed to prediction and prevention of written language disorders in glioma patients undergoing awake surgery, and it has resulted in a valid examination tool to carefully monitor reading and spelling in this patient group.
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Davies, Elizabeth. "The quality of survival of patients with malignant cerebal glioma following radiotherapy." Thesis, Queen Mary, University of London, 1998. http://qmro.qmul.ac.uk/xmlui/handle/123456789/1664.

Повний текст джерела
Анотація:
Objective- To describe survival, disability and morbidity after radiotherapy for malignant glioma and explore patient and relative experience. Design - Home follow-up of patients and relative over up to 24 months and of relatives after bereavement. Setting - Six London hospitals Subjects- 92 patients receiving radiotherapy (83 recruited at diagnosis; 9 after radiotherapy) and 85 relatives. 56 bereaved relatives. Main outcome measures- Survival, time free from disability, and changes in disability after treatment assessed, or deduced retrospectively, using interviewer observation, patient and relative reports, case note review and discussion with medical staff. A semi-structured interview designed for the study assessed awareness of the likely prognosis, distress, dissatisfaction with radiotherapy and perception of severe problems in everyday life. Results - 6,12 and 24 month survivals were 70%, 39% and 10%. Age, World Health Organisation clinical performance status, extent of surgery, and epilepsy each influenced survival. The Medical Research Council prognostic index was also significantly related to survival. Multivariate analysis showed that initial clinical performance status was the most important aspect of the index. Most (80%;4 9/61) patients with a clinical performance status of 0,1 or 2 lived at least 6 months before becoming permanently disabled. Of those with an initial good clinical performance status( 0-2) who survived 6 months after radiotherapy 69% (36/52) experienced either clinical deterioration or severe tiredness after treatment. Severely disabled patients (clinical performance status 3 or 4) gained little benefit. 75 patients and 66 relatives were interviewed at diagnosis, 59 patients after radiotherapy and 27 after deterioration. As they began radiotherapy most patients understood that they suffered from a brain tumour (95% ;7 1/75), but only one quarter (19/75) seemed fully aware of the poor prognosis. Others were unaware (43%; 32/75) or only partly aware (32%; 24/75). The more aware patients were more distressed. Relatives were three times more likely to be aware of the prognosis (67%; 44/66) and were more distressed. Although 39% (29/75) of patients initially made negative comments about radiotherapy, only 17% (13/75) were completely dissatisfied. The decision to accept radiotherapy could be discussed directly with 19 fully aware patients. Twelve found radiotherapy acceptable if it were medically advised or if it improved survival. Assessed by their own reports of symptoms only 40% of patients improved or achieved a period of stability, yet dissatisfaction with treatment did not increase. Bereaved relatives' judgements about quality of life and the value of radiotherapy were strongly related to the patient's initial disability and distress. Short periods of survival between six and 12 months were felt worthwhile. Conclusions- Severely disabled patients gain little benefit from radiotherapy and those not so disabled may experience considerable adverse effects. The lack of awareness of the prognosis, however, makes it difficult to explore with patients directly the possible trade off between quality and length of life. Relatives were more aware, more distressed and often concerned to protect patients from full awareness. However most aware patients accepted radiotherapy for the chance of improved survival and bereaved relatives valued relatively small periods of survival free from disability and distress. Conceptualising these questions as rational choices ignores therefore the social and emotional context of life threatening disease.
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Chikada, Ai. "A descriptive analysis of end-of-life discussions for high-grade glioma patients." Doctoral thesis, Kyoto University, 2021. http://hdl.handle.net/2433/264666.

Повний текст джерела
Анотація:
京都大学
新制・課程博士
博士(人間健康科学)
甲第23385号
人健博第92号
新制||人健||6(附属図書館)
京都大学大学院医学研究科人間健康科学系専攻
(主査)教授 田村 恵子, 教授 稲富 宏之, 教授 溝脇 尚志
学位規則第4条第1項該当
Doctor of Human Health Sciences
Kyoto University
DFAM
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Cavers, Debbie Grant. "Understanding the supportive care needs of glioma patients and their relatives : a qualitative longitudinal study." Thesis, University of Edinburgh, 2010. http://hdl.handle.net/1842/10630.

Повний текст джерела
Анотація:
Background: Malignant cerebral glioma is a rare cancer but has a devastating impact on patients and their families. In Scotland each year, around 450 people are diagnosed with glioma. Prognosis is generally poor and treatment is essentially palliative. There is a growing recognition that non-clinical aspects of care for both patients and their families need to be acknowledged and integrated into health care provision in line with a patient-focused ethos of care. Currently, there is relatively little research exploring the psychosocial issues and needs of this patient group. Aims: To give patients being investigated for malignant cerebral glioma and their families the opportunity to describe their shared experiences of their illness journey and voice their concerns and unmet needs. To examine how these experiences and needs change over time as the patient progresses through the illness journey. To ascertain the extent to which these needs are recognised and supported, taking into accounts professionals’ views and making suggestions for steps forward in improving patients’ psychosocial care. Methods: A total of 80 qualitative prospective longitudinal interviews (30 paired and 50 separate) were conducted with 26 people with a suspected or confirmed diagnosis of malignant cerebral glioma being treated at a regional hospital and 24 primary relative/informal carers. Patients and carers were interviewed at the following five times: leading up to diagnosis; following a formal diagnosis; around the end of initial treatment (radiotherapy); at a designated six-month follow-up stage; and bereavement interviews with carers. One-off interviews were carried out with 66 health professionals (19 case-linked GPs and 47 other health, health-related and social care professionals involved in patients' care). Interviews were recorded and transcribed verbatim and analysed using the constant comparative method from a grounded theory approach assisted by QSR NVivo Version 7. Findings: Distress, anxiety and shock were overwhelming reactions in the period leading up to a diagnosis of glioma, making it difficult for participants to make sense of their experience. Over time, participants employed a range of strategies in order to cope with their diagnosis. Social and emotional support from professionals and friends, family and other patients were vital in many cases but support often felt inadequate. The role of information and the manner in which it was communicated was closely linked to participants’ ability to cope. Information needs were variable but on the whole patients and carers did not feel well informed. Dealing with cognitive and physical symptoms of their illness and side effects of treatment inhibited patients’ ability to resume their everyday activities. The lives of relatives were also affected as they struggled to care for their loved ones. People with a diagnosis of glioma were faced with the possibility of death from an early point in their illness trajectory and awareness of this, coupled with ability to make sense of existential issues, varied across participants. Issues around support, communication, information and palliative care were considered to be important among health professionals involved in the care of people with a diagnosis of glioma but provision fell short. Conclusions: Concerns regarding information, communication and support reported elsewhere in the literature are enduring in glioma patients and their relatives. Reporting of unmet psychosocial and supportive care issues by patients and recognition by professionals of the need to improve these dimensions of care for people affected by glioma emphasises previous recommendations yet to be fully implemented into patient care.
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Coget, Arthur. "Etude et modélisation de la plasticité cérébrale chez des patients porteurs de lésions gliales de bas grade opérés en chirurgie éveillée." Thesis, Montpellier, 2020. http://www.theses.fr/2020MONTS053.

Повний текст джерела
Анотація:
Introduction Les gliomes de bas grade sont des tumeurs cérébrales de progression lente qui affectent l’adulte jeune. Ce mode d’évolution laisse le temps aux réseaux neuraux de se réorganiser de façon massive ce qui permet d’expliquer pourquoi les patients ne présentent habituellement aucun déficit neurologique au diagnostic bien que la tumeur concerne des zones dites «éloquentes». Ces lésions sont donc un sujet d’étude particulièrement intéressant dans la compréhension des mécanismes de plasticité cérébrale.Ces patients bénéficient, comme traitement optimal, d’une chirurgie en condition éveillée permettant une résection la plus importante possible tout en préservant les fonctions neurologiques du patient pour qu’il conserve la meilleure qualité de vie possible.L'imagerie fonctionnelle de repos est un outil robuste en IRM pour étudier la connectivité fonctionnelle et la plasticité cérébrale. Elle est basée sur l’analyse du signal BOLD et présente plusieurs avantages : 1) la possibilité d’être réalisée chez des patients non coopérants 2) la possibilité d’analyser l’ensemble des réseaux neuraux simultanément.Dans ce travail nous souhaitions mesurer les fluctuations de connectivité fonctionnelle durant la période péri-opératoire d’une chirurgie éveillée pour gliome diffus de bas grade afin d’évaluer la plasticité fonctionnelle engendrée par la résection de la tumeur.Dans un second temps, nous avons tenté d'expliquer ces données fonctionnelles péri-opératoires à l’aide de l’imagerie multimodale en analysant l’évolution péri-opératoire de la connectivité anatomique et des paramètres hémodynamiques.Méthodes L’analyse principale portait sur une cohorte de 82 patients porteurs de gliomes diffus de bas grade et opérés en chirurgie éveillée. Pour chaque patient une IRM avec séquences fonctionnelles de repos était réalisée à trois temps : pré-opératoire, post-opératoire immédiat et lors du suivi à 3 mois. Toutes les IRM étaient effectuées pour chaque patient sur la même machine au cours du suivi, soit un système IRM 3.0 Tesla (Skyra, Siemens), soit un système IRM 1.5 Tesla (Avanto, Siemens). Après des étapes classiques de prétraitement, les données fonctionnelles étaient traitées à l’aide du logiciel CONN v16.a.La connectivité anatomique a secondairement été analysée par imagerie de diffusion anisotropique en IRM en se concentrant sur le corps calleux.Enfin les conséquences hémodynamiques de la chirurgie étaient évaluées d’une part via des séquences de perfusion en IRM et d’autre part par une analyse innovante du signal BOLD.RésultatsNous avons constaté de façon surprenante, durant la période post-opératoire immédiate, une altération significative transitoire globale quasi-exclusive de la connectivité interhémisphérique entre régions miroirs, nommée connectivité homotopique.Des modifications de connectivité anatomique concernant le corps calleux et des modifications hémodynamiques régionales et globales ont également été constatées de façon concomitante en période post-opératoire immédiate et à plus long terme après la chirurgie sans qu’un lien direct avec nos données fonctionnelles n’ait pu être mis en évidence.L’analyse des données hémodynamiques a enfin mis une lumière une région intéressante : le striatum. Cette structure pourrait être une région centrale dans le maintien de la connectivité homotopique et son atteinte alors mener aux modifications fonctionnelles observées.Conclusion La rupture d’homotopie fonctionnelle transitoire que nous constatons en période post-opératoire immédiate est probablement d’origine multifactorielle. La prise en compte des données anatomiques et hémodynamiques, dans l’interprétation des résultats fonctionnelles en IRM, est indispensable tant en période post-opératoire immédiate que à plus long terme après la chirurgie. Des travaux d’analyse de la vasoréactivité cérébrale d’une part et de modélisation d’autre part pourraient aider à mieux comprendre les différents phénomènes intriqués
IntroductionDiffuse low-grade gliomas (DLGG) are slow-growing brain tumors occurring in young adults. This slow progression induces extensive neuroplasticity and explains why patients most of the time do not show any obvious neurological deficit at the time of diagnosis although tumors are located in ‘eloquent’ areas. Therefore DLGG provide an interesting model in understanding mechanisms of neuroplasticity.Awake surgery with direct cortical and subcortical electrostimulation mapping is recommended as first-line treatment of DLGG, allowing to maximize tumoral resection and limiting postoperative neurological deficit, maintaining patients quality of life.Resting-state fMRI, based on BOLD signal analysis, is used to study functional connectivity and neural plasticity. This technique allows robust evaluation of neural networks without performing a task. Consequently, it bypasses the impact of confusion, sedation or neurological deficits on task execution. In this thesis, we aimed to investigate perioperative functional connectivity modifications in order to evaluate neural plasticity after awake surgery.Subsequently we explained the functional results using multimodal MRI imaging to analyze anatomic connectivity and hemodynamic parameters.Methods82 patients with DLGG who underwent awake surgical resection were included in the principal study. MRI acquisitions were performed successively before, within 36 h after and three months post-surgery. All scans were executed on the same MRI magnet for each patient, i.e. either a 3.0 T magnet (Skyra, Siemens) or a 1.5 T magnet (Avanto, Siemens). First, data were preprossed using a standardized classical pipeline and analyzed with the CONN toolbox v16.a.Second, anatomic connectivity was evaluated using diffusion tensor imaging of the corpus callosum.Finally hemodynamic changes induced by surgery were assessed with traditional perfusion imaging as well as using an innovative analysis of the BOLD signal’ s temporal shift.ResultsSurprisingly, it was found that specifically a diffuse transient postoperative interhemispheric disconnectivity occurred between homologous regions, known as homotopic connectivity.In parallel, immediate and long-term postoperative alterations in the anatomic connectivity of the corpus callosum were observed. Immediate and long-term postoperative modifications were also found regarding both regional and global hemodynamics characteristics. Yet, no significant link between the homotopic connectivity findings and the anatomical and hemodynamic changes could have been established at this point.Nevertheless, the hemodynamic analysis allowed the identification of a a specific brain region : the striatum. It was hypothesized that it acts as a central region for the maintenance of homotopic connectivity, explaining simultaneously the decreased post-surgical homotopic connectivity observed.ConclusionThe highlighted transient postoperative functional homotopy is probably due to multifactorial causes To start entangling these causes, the use of anatomic and hemodynamic imaging data analyses seems crucial to interpret functional connectivity data both immediate and long-term postoperative.Cerebral vasoreactivity and modelling studies provide thereby a very promising tool to better understand the interrelated processes underlying postoperative functional connectivity modifications
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Книги з теми "Glioma patients"

1

Elizabeth, Davies, and Hopkins Anthony, eds. Improving care for patients with malignant cerebral glioma. London: Royal College of Physicians, 1997.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Binding distribution and cellular uptake of Na2B12H11SH (BSH) in tumor tissue of glioma patients: Investigations for boron neutron capture therapy. Aachen: Shaker, 1997.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Guerrero, Douglas. A retrospective analysis investigating the prevalence of epilepsy in patients with gliomas. [Guildford]: [University of Surrey], 1994.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

(Editor), Elizabeth Davies, and Anthony Hopkins (Editor), eds. Improving Care for Patients with Malignant Cerebral Glioma. Royal College of Physicians of London, 1997.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Sanai, Nader. Low-Grade Gliomas. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190696696.003.0027.

Повний текст джерела
Анотація:
Low grade gliomas encompass multiple histologic diagnoses of primary brain tumors, most commonly grade 2 oligodendroglioma and grade 2 astrocytoma. This chapter presents a case of a patient with a left temporal low grade glioma who presented with seizures, which are a common presenting symptom for this tumor type. Management of patients with a newly diagnosed low grade glioma typically begins with maximal safe surgical resection for surgically accessible tumors. Surgical planning may involve functional imaging such as with fMRI. Genetic and molecular markers help distinguish subtypes of low grade gliomas, and this subtyping has implications for the type and timing of adjuvant therapy.
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Kaley, Thomas J. Oligodendrogliomas. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199937837.003.0128.

Повний текст джерела
Анотація:
Gliomas represent the most common symptomatic primary brain tumors, of which oligodendrogliomas are the least common subtype of glioma.1 The traditional thinking is that although the rarest, they also offer patients the best prognosis and they are deemed to be the most sensitive to treatment. However, although they may have a longer average survival than most other gliomas, nearly all patients with an oligodendroglioma will ultimately succumb to their illness due to either progressive and recurrent tumor or malignant transformation into a higher grade tumor. Optimal treatment of oligodendroglial tumors, especially those harboring a 1P/19Q codeletion, remains controversial.
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Weller, Michael, Michael Brada, Tai-Tong Wong, and Michael A. Vogelbaum. Astrocytic tumours: diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, and gliomatosis cerebri. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199651870.003.0003.

Повний текст джерела
Анотація:
Astrocytic gliomas are primary brain tumours thought to originate from neural stem or progenitor cells. They are assigned grades II, III, or IV by the World Health Organization according to degree of malignancy as defined by histology. The following molecular markers are increasingly used for diagnostic subclassification or clinical decision-making: 1p/19q co-deletion status, O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, and isocitrate dehydrogenase 1 and 2 mutation status. Extent of resection is a favourable prognostic factor, but surgery is never curative. Radiotherapy prolongs progression-free survival across all astrocytic glioma entities. Alkylating agent chemotherapy is an active treatment in particular for patients with MGMT promoter-methylated tumours. Anti-angiogenic therapies have failed to improve survival, and the current focus of major clinical trials is on novel targeted agents or on immunotherapy.
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Huntoon, Kristin, and J. Bradley Elder. High-Grade Gliomas. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190696696.003.0001.

Повний текст джерела
Анотація:
Glioblastoma is the most common primary malignant brain tumor. This chapter discusses the clinical presentation and initial workup for a patient with a suspected glioblastoma, as well as the optimal treatment strategy and prognosis. Diagnosis is typically made using magnetic resonance imaging. Optimal treatment involves maximal safe surgical resection followed by adjuvant chemotherapy and radiation therapy. Surgical adjuncts including intraoperative imaging modalities and brain mapping techniques help improve neurologic morbidity associated with surgery. Despite maximal treatment, virtually all patients with glioblastoma will experience recurrence of their tumor and may be considered for clinical trials or second-line therapy. This chapter highlights important pearls associated with management of patients with glioblastoma and written for those who are interested in neuro-oncology, neurosurgery, and the field of brain tumors.
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Taillandier, Luc, Laurent Capelle, and Hugues Duffau. New Therapeutic Strategies in Low-grade Gliomas. Nova Science Publishers, 2006.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Eseonu, Chikezie I., Jordina Rincon-Torroella, and Alfredo Quiñones-Hinojosa. Unusual Gliomas. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190696696.003.0002.

Повний текст джерела
Анотація:
Patients with intra-axial brain tumors often present with neurologic symptoms based on the anatomic location of their tumor. Workup for a brain tumor includes cranial imaging such as magnetic resonance imaging and computed tomography, as well as systemic imaging to assess for primary tumor if metastasis is suspected. Maximal safe resection optimizes outcomes including overall survival. Surgical decisions are based on variables such as medical comorbidities and anatomic location of the tumor. Gliomas in eloquent areas may require intraoperative cortical and subcortical mapping of motor and/or language areas to optimize safety and help maximize resection. Adjuvant chemotherapy and radiation lead to a median survival of 14.6 months for patients with glioblastoma. Rapidly recurring glioblastoma after surgery has a poor prognosis.
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Частини книг з теми "Glioma patients"

1

Fujiwara, S. "Clinical Study Using MRI in Patients Treated with RAFP Therapy." In Treatment of Glioma, 231–40. Tokyo: Springer Japan, 1988. http://dx.doi.org/10.1007/978-4-431-68453-4_15.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Mori, T. "The Pharmacokinetics of ACNU in Patients with Malignant Brain Tumor." In Treatment of Glioma, 109–16. Tokyo: Springer Japan, 1988. http://dx.doi.org/10.1007/978-4-431-68453-4_4.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Puumalainen, Anu-Maaria, Matti Vapalahti, and Seppo Ylä-Herttuala. "Gene Therapy for Malignant Glioma Patients." In Advances in Experimental Medicine and Biology, 505–9. Boston, MA: Springer US, 1998. http://dx.doi.org/10.1007/978-1-4615-5357-1_78.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Fankhauser, Heinz, Giuseppe Stragliotto, and Pascal Zbinden. "Borocaptate Sodium (BSH) Pharmacokinetics in Glioma Patients." In Boron Neutron Capture Therapy, 155–62. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3408-2_17.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Smits, Anja, and Anette Storstein. "Tumor-Associated Epilepsy in Patients with Glioma." In Tumors of the Central Nervous System, Volume 2, 397–406. Dordrecht: Springer Netherlands, 2011. http://dx.doi.org/10.1007/978-94-007-0618-7_39.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Walbert, Tobias, and Kristen Chasteen. "Palliative and Supportive Care for Glioma Patients." In Cancer Treatment and Research, 171–84. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-12048-5_11.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Ham, Timothy, and Timothy Rittman. "Neurological Assessment of Patients with Gliomas." In Management of Adult Glioma in Nursing Practice, 37–48. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-76747-5_3.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Herold-Mende, Christel, and Benito Campos. "Glioma Patients: Role of CD133 Stem Cell Antigen." In Stem Cells and Cancer Stem Cells, Volume 1, 69–76. Dordrecht: Springer Netherlands, 2011. http://dx.doi.org/10.1007/978-94-007-1709-1_8.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Kaprelyan, A. G., N. M. Mincheva, K. T. Metodiev, D. M. Minchev, and D. S. Cholakov. "Immunologic Monitoring in Patients with Glioma Treated Neurosurgically." In Immunology and Its Impact on Infections in Surgery, 196–99. Berlin, Heidelberg: Springer Berlin Heidelberg, 1995. http://dx.doi.org/10.1007/978-3-642-79079-9_28.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Maeda, Tatsuhiro, Kazuhiko Saruta, Satoyuki Ito, Hiroki Sawa, and Isamu Saito. "Efficiency of Glioma Score in Glioma Patients Using Proliferating Potential with MIB-1 Monoclonal Antibody." In Brain Tumor, 141–48. Tokyo: Springer Japan, 1996. http://dx.doi.org/10.1007/978-4-431-66887-9_15.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Glioma patients"

1

Hayashi, Shigeto, Atsushi Sakuma, Takashi Sasayama, and Eiji Kohmura. "Measurement of Glioma Viscoelasticity Using a Handheld Palpation Imitation Device." In ASME 2017 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2017. http://dx.doi.org/10.1115/imece2017-70835.

Повний текст джерела
Анотація:
We examined glioma tissues immediately after en-bloc removal during surgery and measured elastic modulus, viscosity, and viscoelasticity of the gray and white matter to confirm the feasibility of measurement using an indentation device. Measurements were obtained from excised parenchymal brain tumor tissue of four adult patients. The white matter exhibited higher elastic modulus than the gray matter in all patients. Viscoelasticity analysis was performed in two patients, with viscoelastic behavior observed in the white but not in the gray matter in both patients. The loss of viscoelasticity in the white matter observed in one patient may be related to the calcification visible in the preoperative computed tomography image.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Ben Abdallah, Meriem, Marie Blonski, Sophie Wantz-Mezieres, Yann Gaudeau, Luc Taillandier, and Jean-Marie Moureaux. "Predictive models for diffuse low-grade glioma patients under chemotherapy." In 2016 38th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). IEEE, 2016. http://dx.doi.org/10.1109/embc.2016.7591692.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Wijethilake, Navodini, Dulani Meedeniya, Charith Chitraranjan, and Indika Perera. "Survival prediction and risk estimation of Glioma patients using mRNA expressions." In 2020 IEEE 20th International Conference on Bioinformatics and Bioengineering (BIBE). IEEE, 2020. http://dx.doi.org/10.1109/bibe50027.2020.00014.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Papp, L., S. Rasul, M. Weber, M. Grahovac, T. Beyer, M. Hacker, and T. Traub-Weidinger. "Understanding gender pattern differences in MET-PET Glioma patients with radiomics analysis." In NuklearMedizin 2020. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1708295.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Boisselier, Blandine, Marianne Labussiere, Marta Rossetto, Jaime Gallego Perez Larraya, Yannick Marie, Jean-Yves Delattre, and Marc Sanson. "Abstract 5559: Detection of IDH1 mutation in the plasma of glioma patients." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-5559.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Voigt, Tobias. "Imaging conductivity using electric properties tomography — Initial clinical results in glioma patients." In 2011 XXXth URSI General Assembly and Scientific Symposium. IEEE, 2011. http://dx.doi.org/10.1109/ursigass.2011.6051346.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Pescatello, Meredith, Nimish Mohile, Jennifer Serventi, Bethann Sayers, Jacqueline Behr, Lauryn Hemminger, and Sara Hardy. "Structured Early Advanced Care Planning Outcomes for Patients with High Grade Glioma (S17.006)." In 2023 Annual Meeting Abstracts. Lippincott Williams & Wilkins, 2023. http://dx.doi.org/10.1212/wnl.0000000000203293.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Sharma, Puja, Brian Koons, and Amrinder S. Nain. "Blebbing Dynamics, Single Cell Force Measurements, and the Influence of Cytochalasin D on Glioblastoma Multiforme Cells Using STEP Fibers." In ASME 2013 2nd Global Congress on NanoEngineering for Medicine and Biology. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/nemb2013-93105.

Повний текст джерела
Анотація:
Classified as a grade IV tumor of the central nervous system, Glioblastoma multiforme (GBM) arises from the glia. A poor understanding of tumor metastasis and limited treatment options have led to increase in deaths of patients suffering from GBM. Studying glioma behavior using aligned structures that mimic native glioblastoma metastatic path is challenging. In this study, we utilize a previously described non-electrospinning platform to manufacture aligned 3D structures called STEP nanonets that not only allows the study of individual cell-nanofiber interaction, but also allows the calculation of migratory forces using beam mechanics. In particular, the blebbing dynamics, force generation, and the effect of an actin disruptor, Cytochalasin D have been investigated on a glioma cell line (DBTRG, Denver Based Tumor Research Group). It was observed that cell pulled onto the nanofibers causing measurable deflections when they were in spread and non-blebbing conditions. In non-spread configurations while attached to fibers, the cells acquired spherical configurations and resumed blebbing. The average migratory force generated by cells exposed to DMSO (control, 1:1000 dilution) using nanonets of 2μm by 400nm fibers was 0.58±0.06nN. Actin disruptor, Cytochalasin D severely compromised the ability of the glioma cells to migrate causing no deflection of the fibers. Forces exerted by tumor cells on their native microenvironment affects their ability to metastasize, invade and proliferate. While the result presents actin disruptor as a potential target to minimize metastasis, the influence of other cytoskeleton disruptors can also be studied using the platform. Moreover, the results obtained from the study can be utilized to better understand the individual cell – nanofibers interaction which can shed light on how cells interact with their native environment during metastasis.
Стилі APA, Harvard, Vancouver, ISO та ін.
9

rathore, saima, Spyridon Bakas, Hamed Akbari, MacLean P. Nasrallah, Stephen Bagley, and Christos Davatzikos. "Abstract 1392: Machine Learning Radiomic Biomarkers Non-invasively Assess Genetic Characteristics of Glioma Patients." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-1392.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

rathore, saima, Spyridon Bakas, Hamed Akbari, MacLean P. Nasrallah, Stephen Bagley, and Christos Davatzikos. "Abstract 1392: Machine Learning Radiomic Biomarkers Non-invasively Assess Genetic Characteristics of Glioma Patients." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-1392.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Glioma patients"

1

Yang, Chao, Tao-junjin Lu, Jie Wang, Qing Zhang, Ze-Fen Wang, and Zhi-Qiang Li. Association of systemic immune-inflammation index with grade and prognosis in glioma patients: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2022. http://dx.doi.org/10.37766/inplasy2022.4.0072.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Yin, Liangyu, Feifei Chong, Zhenyu Huo, Na Li, Jie Liu, and Hongxia Xu. GLIM-defined malnutrition and overall survival in cancer patients: A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2022. http://dx.doi.org/10.37766/inplasy2022.7.0113.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Також вас можуть зацікавити розширені добірки на тему "Glioma patients" для конкретних типів джерел:
Статті в журналах Дисертації Книги
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії